Auro Laboratories Limited has submitted unaudited Financial Results for the quarter and half year ended September 30, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 17.1 pts more than Nifty Microcap 250 and 17.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Auro Laboratories, a single-segment pharmaceuticals company, posted Q2 FY26 revenue from operations of Rs 883.67 lakhs, jumping roughly 185% from Rs 310.12 lakhs in Q2 FY25. Q2 profit after tax doubled to Rs 71.58 lakhs (from Rs 35.81 lakhs), with basic EPS rising to Rs 1.48 from Rs 0.57. For H1 FY26, total income grew to Rs 1,300.32 lakhs from Rs 933.23 lakhs, but half-yearly PAT slipped to Rs 61.03 lakhs (from Rs 111.08 lakhs) because of a Rs 100.41 lakh deferred tax charge in the period. The statutory auditor, B.L. Dasharda & Associates, issued an unqualified limited review report. Total assets stood at Rs 11,077 lakhs as on September 30, 2025, up from Rs 9,909 lakhs at March-end 2025, reflecting heavy capital expenditure during the half year.
The sharp Q2 revenue and profit jump signals a meaningful pickup in business momentum, which is positive for the small-cap pharma stock. However, investors should be mindful of the rising debt load (total borrowings around Rs 4,394 lakhs against equity of about Rs 4,358 lakhs) and sharply higher finance costs and depreciation that compressed the EBITDA margin.